Cepheid and bioMerieux Enter into Strategic Agreements
News Jan 18, 2007
Cepheid and bioMerieux has announced that they have entered into a strategic relationship wherein both companies will use their respective technologies and commercial strengths towards the development and commercialization of an innovative line of sepsis test products on the GeneXpert platform.
Companies will jointly develop the products, Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive worldwide basis.
The product menu will comprise both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. Cepheid will continue to complete development, manufacture and market the MRSA products.
“We are extremely excited about our relationship with Cepheid,” said bioMérieux CEO Stephane Bancel.
“Together, we will create the next generation of molecular diagnostics systems, leveraging bioMerieux’s blood culture and immunology solutions and its deep biology expertise with Cepheid’s unique system and reagent development experience, all focused on ease of use in highly clinically relevant situations.”
“Together, we will bring nucleic acid diagnostics into routine clinical use to places and applications where it is needed most. This agreement strengthens our 2007-2012 strategy because sepsis is one of our strategic diseases and we want to expand our molecular biology commercial offer,” Bancel continued.
“Our GeneXpert® system represents a paradigm shift in molecular diagnostic automation which we expect will bring new capabilities and benefits to medical institutions and clinicians directly. This new partnership with bioMerieux in the area of sepsis is consistent with our focus on leveraging our GeneXpert technology in high-value, high-impact settings in which critical diagnostic information is available on-demand” said Cepheid CEO John Bishop.
“By rapidly determining the major causes of sepsis and providing a molecular snapshot of drug resistant organisms including MRSA, the GeneXpert system will allow clinicians to make informed treatment decisions much sooner than with other currently available methods.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.